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mobility of the COMP digested fragment. In addition, EDTA chela- 
tor totally abolished the enzymatic activity. Take together; Zinc is 
essential for the ADAMTS7-mediated COMP degradation. 
Cleavage of COMP by ADAMTS-7 is pH-dependent- ADAMTS- 
7 generated the largest amount of COMP fragments in the range 
of physiological pH (pH 7.5) up to pH 9.5, whereas the enzyme 
did not produce visible COMP fragments when pH values lower 
than 6.5 or higher than 10.5, indicating that the digestive activity 
of ADAMTS-7 is also pH-dependent. 
Increased expression of ADAMTS-7 in the cartilage and syn- 
ovium of patients with rheumatoid arthritis - To determine 
whether the expression of ADAMTS-7 in cartilage and synovium 
is altered in OA and/or RA, a real-time PCR was performed. 
ADAMTS-7 mRNA was significantly upregulated in RA cartilage, 
and only slightly upregulated in OA cartilage, compared to the 
normal control. Further analysis of synovium samples revealed 
that the level of ADAMTS-7 was also significantly upregulated in 
RA synovium compared to normal synovium. 
Conclusion: ADAMTS-7 digests COMP in a Zn 2+- and pH- 
dependent manner. ADAMTS-7 is significantly upregulated in car- 
tilage and synovium obtained from patients with RA, suggesting 
that ADAMTS-7 plays an important role in joint degenerative dis- 
ease progression. 
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Most drugs inhibiting bone resorption used in the treatment of 
osteoporosis decrease excretion of cartilage degradation mark- 
ers and some of them stimulate chondrocytes and showed a pro- 
tective effect on experimental arthropathies in animals. Among 
them, estrogens and raloxifene (RLX), SERM group, not only in- 
hibit bone resorption but also act receptively on chondrocytes. 
Estrogens and HRT retarded progress of knee osteoarthritis but 
there is no evidence concerning a similar effect of RLX. In our par- 
allely published work, there were statistically significant improve- 
ment of mean of WOMAC index which corelated with decrease of 
CTX-II excretion. 
The aim of the study was to evaluate the effect of the 12-month- 
therapy with RLX in middle-aged women with knee osteoarthri- 
tis (OAK) and osteopenia on cartilage degeneration and bone 
turnovers markers. 
The study was conducted in 65 women, aged 52-79, mean 65.4 
years, with diagnosed OAK according to ACR criteria and rated 
on a 3-point Kellgren - Lawrence scale, with low bone mass (BMD 
of Hip neck and/or L1-L4 vertebrae T-score between -1.0 and - 
2.5), without contraindications to be treated with RLX. Patients 
were randomly assigned in the approximate ratio 1:2 to the con- 
trol (C), or to group (E) being treated for 12 mounts with 60 mg of 
RLX p.o. per day. All the participants took Calcium up to 1200 
mg/d plus 800 IU Vit. D3 and Tramadol 1-2 x 50mg/24 hours 
in the case of pain. The evaluation of RLX effect on joint car- 
tilage was based on measurements of excreted with urine the 
cartilage-specific C-terminal tetrapeptide of type II collagen CTX- 
II/Cr and cartilage oligometric matrix protein (COMP) with ELISA 
method. The bone turnover was monitored with bone-specific al- 
kaline phosphatase (b-ALP), osteoprotegerin (OP), bone-specific 
C-terminal tetrapeptide of type I collagen (CTX-I), and soluble 
NF-kappa-B receptor activator (sRANKL) with ELISA method. 
The patients and markers were monitored before and after 3, 6, 
and 12 months of treatment with RLX. 
Results: Regressive analysis of time changes showed statisti- 
cally significant decrease in OP, CTX-II, CTX-II/Cr in the group 
treated with RLX and lack of any marker changes in the con- 
trol group. The drop of excreted CTX-II and CTX-II/Cr after 12 
months in group E was 30% and 40%, respectively with regard to 
the values before the treatment. There were neither differences 
in time and between the groups E and C as for markers of bone 
metabolism nor their correlation with markers of cartilage degen- 
eration nor COMP changes. 
Conclusion: We observed a statistically significant decrease 
in CTX-II and CTX-II/Cr excretion (with simultaneous ignificant 
lowering of WOAC index) in patients treated with RLX as com- 
pared to lack of such changes in the control group. It seems that 
RLX has a curative effect on cartilage degradation with improve- 
ment of clinical outcomes. There was no evidence on interaction 
between cartilage and bone metabolismexcept of decrease of OP. 
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Background: Collagen induced arthritis in the rat has been ex- 
tensively studied as a model of rheumatoid arthritis (RA). Dis- 
ease activity and structural joint damage can be quantitatively as- 
sessed, and in addition biochemical markers have been adopted 
in the monitoring of disease progression in the CIA model. Helical 
fragments of type II collagen (C2C), which are generated by the 
action of aggrecanase, are slightly increased in the CIA model 
(Mayer et al, JBMR 2004;19:SA030). However, other proteases 
participating in the degradation of articular cartilage give rise to 
other collagen fragments, and therefore the present study was 
undertaken to investigate if fragments of C-telopeptide of type II 
collagen (CTX II) in circulation could reflect disease activity in this 
animal model of RA. 
Objective: To investigate the time-course of collagen type II 
degradation in circulation in the CIA model of rheumatoid arthrti- 
tis. 
Methods: Twenty, 6-week old female Lewis (LEW/SsN/CrCrlBR) 
rats were randomized into 2 groups: (I) CIA group (15 animals) 
and (11) negative control (5 animals). The immunization was 
performed once at Day 1 with porcine type II collagen. Blood 
samples were collected at day 1 (prior to immunization), 8, 15, 
18 and 23, and in addition, lavage synoviocentesis was per- 
formed at study termination. Cartilage degradation was evalu- 
ated using serum CTX-II (Nordic Bioscience, Denmark) and C2C 
(Ibex, Canada) assays. Bone resorption was estimated by CTX-I 
(Nordic Bioscience, Denmark). Paw inflammation was assessed 
semi-quantitatively using scores from 0 to 5. 
Results: CIA group developed arthritis at Day 15 after immuniza- 
tion. The cumulative macroscopic scores from tarsal and carpal 
joints (left and right) were 0.0 and 9.1 4- 1.6 (p = 0.0012) in neg- 
ative and CIA groups, respectively. Serum CTX II levels were in- 
creased 295% compared to controls at Day 15 (p = 0.0012). C2C 
was increased 12% in the CIA group, which, however, did not 
reach statistical significance. The cumulative macroscopic scores 
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at day 15 correlated with serum CTX-II (r = 0.72, p = 0.0004), but 
not with C2C (p = 0.132). Synovial CTX II measured at termina- 
tion day was 251.9 4- 118.3 pg/ml (mean 4- SD) and 7.64 4- 1.65 
pg/ml in CIA and control groups, respectively. Finally, serum CTX- 
I did not shown any differences between groups until day 23. At 
Day 23, a 66% elevation in bone resorption was observed in the 
CIA animals compared to control group (p < 0.05). 
Conclusion: C-telopeptide, but not helical, fragments of type II 
collagen is dramatically elevated in serum and synovial fluid as 
early as two weeks after immunization with type II collagen in the 
rat CIA-model. This accelerated cartilage degradation occurs si- 
multaneously with disease onset as evaluated by paw inflamma- 
tion. These observations suggest, that proteases different from 
aggrecanase are expressed early in this model of RA. 
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Aim: Type II collagen is abundantly and specifically found in car- 
tilage and its degradation generates fragments such as HELIX-II 
and CTX-II. These fragments, which originate from the triple heli- 
cal and C-telopeptide regions respectively, can be quantified us- 
ing specific immunoassays (Syncart TM and Cartilaps~u). Urinary 
HELIX-II and CTX-II concentrations are elevated in conditions of 
cartilage degradation, although their respective levels differ in OA 
and RA patients suggesting distinct collagenolytic pathways. The 
enzymes capable of cleaving type II collagen to release these 
fragments are currently unknown. We investigated the ability of 
cathepsins (Cat) and matrix metalloproteases (MMP) to digest 
native articular cartilage and to release the CTX-II and HELIX-II 
biomarkers. 
Methods: Human hip articular cartilage (5 mg/mL) was digested 
with 1 I~M human Cat B, L, K, S and D (pH 5.5) and 1 I~M hu- 
man MMP-1, -3, -7, -9 and -13 (pH 7.5) for 24 h at 37°C. The 
digestion of cartilage to release soluble peptides was determined 
by hydroxyproline and HELIX-II and CTX-II were determined by 
specific ELISAs. 
Results: All cathepsins and MMPs solubilised between 10% and 
70% of the native cartilage over 24 h, although the release of 
CTX-II and HELIX-II differed dramatically between enzymes. Cat 
B was the sole cathepsin capable of releasing significant quanti- 
ties of CTX-II, whereas HELIX-II was only released efficiently by 
Cat L and S and to a lower extent by Cat K. CTX-II was released 
by all MMPs tested, although the efficiency differed for each en- 
zyme. HELIX-II was released only by MMP-7, and to a lower ex- 
tent by MMP-3. The addition of MMPs to collagen fragments re- 
leased by Cat K from cartilage in a primary digestion, only re- 
leased small quantities of CTX-II and no further HELIX-II. CTX-II 
produced by cartilage digestion with MMP-7 was not destroyed 
by subequent incubations with cathepsins whereas HELIX-II frag- 
ments were completely cleaved by subsequent incubation with 
Cat B. 
Conclusion: Cathepsins and MMPs can both digest native carti- 
lage in vitro, but only distinct subsets of these enzymes generate 
CTX-II and HELIX-II fragments. These findings may provide a bio- 
logical rationale for the recent observation that the relative urinary 
abundance of HELIX-II and CTX-II differs between RA and OA 
patients and support the concept that specific protease inhibitors 
could be used selectively against given arthritis diseases. 
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Aim of study: to quantitate and determine relative chain lengths 
of HA and CS fragments in serum and synovial fluid. 
Methods: After proteinase K digestion, serum (1 ml) and syn- 
ovial fluid (0.25 ml) samples were fractionated by gel filtration 
columns packed with allyl dextran/bisacrylamide (Sephacryl S- 
1000) or agarose (Superose 6). S-1000 has a fractionation range 
(Mr) of 5×105 to >108 and Superose 6 has a range up to 
106. Larger fragments were eluted first, followed by progressively 
smaller fragments. The columns had values of V0 ~ 6 ml and 
Vt ~ 25 ml. Fractions (1 ml) 7 through 24 were collected and 
analyzed (S-1000 fractions designated A7 - A24 and Superose 
6 fractions designated B7 - B24). For serum, only Superose 
6 fractions were analyzed. Fractions were digested with chon- 
droitinase ACII/ABC and the disaccharide digests were labeled 
with 2-aminoacridone for fluorophore-assisted carbohydrate lec- 
trophoresis (FACE). FACE gels were photographed and analyzed 
with Kodak 1 D software. 
Results: Fluorotagged HA and CS digestion products from 
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Fig 1 HA/0S/6S/4S content in $1000 fractions (A7 A24) and Superose 6
fractions (B7-B24) of synovial fluid and serum from 9 normal horses. A: Syn- 
ovial fluid HA content. B: Synovial fluid CS content. C: Serum HA/0S/6S/4S 
content. 
